Auralis developed generic pharmaceutical products for niche markets, which were subject to licence or regulatory approval providing barriers to entry to protect margin and revenue.

Aquarius assisted management in developing a focussed asset portfolio strategy, which would shape the business to be either floated or would have the critical mass to be of interest to large trade acquirers.